Zymeworks price target raised to $47 from $40 at Stifel

Stifel raised the firm’s price target on Zymeworks (ZYME) to $47 from $40 and keeps a Buy rating on the shares. Meaningful FY26 catalysts include an additional planned OS analysis from HERIZON-GEA-01 in mid-FY26, the likely approval and launch of Zani in first-line GEA in the second half, additional Phase 1 ZW191 dose-escalation/expansion data and multiple presentations from the R&D portfolio at the April AACR meeting, the analyst tells investors.